The agency says it’s open to offering speedy approval pathways for new pain medications that can fight the ongoing opioid ...

The US FDA has issued new guidance on ways to expand development of non-opioid treatment options for chronic pain.

Journavx (suzetrigine) 50 mg oral tablets, the first-in-class non-opioid analgesic for moderate to severe acute pain, was ...

"Immunizations are an effective tool to reduce health risks," according to the Vaccine Integrity Project, based at the ...

By Stephanie Brown HealthDay ReporterWEDNESDAY, Sept. 10, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ...

The FDA has issued new draft guidance to promote safe and effective non-opioid treatments, and to curb prescription-related opioid misuse. In a press release, the FDA said that the cornerstone of the ...

Rapid scientific advances are accelerating the development of medical innovations, from personalized treatments to curative ...

The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and ...

With a flurry of recent Big Pharma investment in radiopharmaceutical therapeutics, the FDA issued draft guidance last month ...

The U.S. Food and Drug Administration approved new COVID-19 shots for this fall, but only for a limited number of Americans. That could make it harder for some to get shots.

A handful of states like Massachusetts, New Jersey, Pennsylvania and New Mexico have recently changed their laws to allow ...

Ocaliva, approved for primary biliary cholangitis, faced FDA warnings and restrictions after postmarket data showed higher ...